1 results match your criteria: "Norton Neuroscience Institute Memory Center[Affiliation]"
Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center.
J Prev Alzheimers Dis
November 2024
Kenneth G. Pugh, MD, MSc, Norton Neuroscience Institute Memory Center, Norton Healthcare, Norton Medical Plaza III- Brownsboro, Suite 300, 4915 Norton Healthcare Blvd. Louisville, KY 40241 U.S.A., (502) 394-6460 (Office); (502) 394-6465 (FAX), E-mail:
Article Synopsis
- The FDA approved lecanemab (Leqembi®) on July 6, 2023, for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease, with early experiences shared from a regional medical center.
- A retrospective study at the Norton Neuroscience Institute Memory Center involved 71 patients, all diagnosed with Alzheimer’s through cerebrospinal fluid biomarkers, most of whom were older, predominantly female, and referred by their primary care providers.
- The study found that 24% of patients experienced amyloid-related imaging abnormalities (ARIA) after treatment, with differences noted between those homozygous and heterozygous for the ApoE4 genotype.